Perfluorobutanesulfonic acid

Perfluorobutanesulfonic acid (PFBS) 是一种短链全氟烷基物质,也是全氟辛烷磺酸的主要替代物,可诱导人 HepG2 肝癌细胞发生脂肪堆积,并通过激活 PPARγ 通路及引发氧化应激、内质网应激和钙稳态失衡来促进脂质堆积,同时会损伤秀丽隐杆线虫的生殖功能并导致其子代出现发育障碍,还会干扰斑马鱼胚胎的胰腺器官发生及脂质稳态,可用于环境毒理学、脂质代谢及发育毒性研究。
产品编号: MS-I52074 纯度: 98.0% CAS No.: 375-73-5 分子式: C4Hf9O3S 分子量: 300.10
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
询价

产品描述

Perfluorobutanesulfonic acid (PFBS) 是一种短链全氟烷基物质,也是全氟辛烷磺酸的主要替代物,可诱导人 HepG2 肝癌细胞发生脂肪堆积,并通过激活 PPARγ 通路及引发氧化应激、内质网应激和钙稳态失衡来促进脂质堆积,同时会损伤秀丽隐杆线虫的生殖功能并导致其子代出现发育障碍,还会干扰斑马鱼胚胎的胰腺器官发生及脂质稳态,可用于环境毒理学、脂质代谢及发育毒性研究。

生物实验数据

生物活性 Perfluorobutanesulfonic acid (PFBS) is a short-chain perfluoroalkyl substance and a major substitute for perfluorooctanesulfonic acid that induces lipid accumulation in human HepG2 hepatoma cells, promotes lipid accumulation by activating the PPARγ pathway and triggering oxidative stress, endoplasmic reticulum stress, and calcium homeostasis imbalance, impairs reproductive function in Caenorhabditis elegans and causes developmental disorders in its offspring, interferes with pancreatic organogenesis and lipid homeostasis in zebrafish embryos, and can be used in environmental toxicology, lipid metabolism, and developmental toxicity research.
IC50 & Target

PPARγ

 

体外研究
(In Vitro)

Perfluorobutanesulfonic acid 可高亲和力结合斑马鱼、大口黑鲈、黑头呆鱼和大西洋鲑鱼的雌激素受体亚型,结合亲和力范围为 -7.4 至 -9.1 kCal/mol,表明其在这些鱼类中具有通过雌激素受体介导内分泌干扰的强潜力。
Perfluorobutanesulfonic acid (PFBS) (50-200 μmol/L; 48 h) 不会降低人肝癌细胞 HepG2 的存活率,无论是否同时暴露于脂肪酸。
Perfluorobutanesulfonic acid (200 μmol/L; 48 h) 与 300 μmol/L 脂肪酸混合物联合处理 48 小时后,可显著增加 HepG2 人肝癌细胞中的甘油三酯蓄积,但在无脂肪酸的情况下无此作用。
Perfluorobutanesulfonic acid (200 μmol/L; 48 h) 可显著上调人肝癌 HepG2 细胞中脂肪生成相关基因 (ACC、FAS、SREBP1、DGAT2)、脂肪酸摄取相关基因 (CD36、PPARγ)、脂肪酸 β-氧化相关基因 (CPT1a、PPARα) 以及内质网应激标志物 CHOP 的 mRNA 表达水平。
Perfluorobutanesulfonic acid (200 μmol/L; 1-12 h) 可显著增加人肝癌 HepG2 细胞内的 ROS 生成。
Perfluorobutanesulfonic acid (200 μmol/L; 1 h) 可显著升高人肝癌 HepG2 细胞中的胞质钙水平。
Perfluorobutanesulfonic acid (200 μmol/L; 48 h) 可通过 PPARγ 依赖通路,在经 300 μmol/L 脂肪酸混合物处理 48 h 后,增加人肝癌 HepG2 细胞内的甘油三酯积累。

Cell Viability Assay

Cell Line: HepG2 human hepatoma cells
Concentration: 50 μmol/L; 100 μmol/L; 200 μmol/L
Incubation Time: 48 h
Result: Exerted no cytotoxic effect on HepG2 cells, either with or without fatty acid treatment.
Maintained cell viability at ~85-105% of control levels across all tested concentrations.

Real Time qPCR

Cell Line: HepG2 human hepatoma cells
Concentration: 200 μmol/L
Incubation Time: 48 h
Result: Upregulated mRNA levels of ACC by 75%, FAS by 98%, SREBP1 by 74%, and DGAT2 by 39%; elevated CD36 by 26% and PPARγ by 47%; increased CPT1a by 149% and PPARα by 67%; and enhanced CHOP expression by 82% versus controls, regardless of fatty acid cotreatment.
体内研究
(In Vivo)

Perfluorobutanesulfonic acid (PFBS) (16-32 µM; daily exposure in 0.3x Danieau’s medium; daily; 1 to 7 dpf) 可显著增加斑马鱼幼鱼的发育缺陷、胰腺形态异常,并干扰其脂质和糖调节基因表达通路。
Perfluorobutanesulfonic acid (8.25-8250 µM; daily exposure in 0.3x Danieau’s medium; daily; 3 hours post fertilization to 5 dpf) 可导致斑马鱼的存活率、孵化率和鳔膨胀率呈剂量依赖性降低。
Perfluorobutanesulfonic acid (PFBS) (1000-2000 μM; in S-complete liquid media with heat-killed E. coli; 1 day exposure) 可显著损伤野生型秀丽隐杆线虫的繁殖能力,且不改变孵化率。
Perfluorobutanesulfonic acid (1000-2000 μM; in vitro in S-complete liquid media with heat-killed E. coli; 2 day exposure) 在 1000 μM 浓度下可使秀丽隐杆线虫胚胎的甘油三酯和蛋白质水平各降低约 24%;此时胚胎内该物质的浓度在 1000 μM 处理组达 1.8 ng/mg DNA,在 2000 μM 处理组达 3.3 ng/mg DNA,而 2000 μM 处理并未导致胚胎营养水平出现显著下降。
Perfluorobutanesulfonic acid (1000-2000 μM; in vitro in S-complete liquid media with heat-killed E. coli; 1 day exposure) 可使转基因秀丽隐杆线虫中作为卵母细胞卵黄摄取标志物的 VIT-2::GFP 荧光强度分别显著降低 25% 和 23%,同时亲本成虫体内的药物浓度可达 2.8 ng/mg DNA 和 4.6 ng/mg DNA。
Perfluorobutanesulfonic acid (1000-2000 μM; in vitro in S-complete liquid media with heat-killed E. coli; 2 day exposure to F0) 可显著延缓秀丽隐杆线虫 F1 代后代的生长速率。
Perfluorobutanesulfonic acid (PFBS) (经水暴露;持续处理;从受精至 120 hpf) 可导致斑马鱼胚胎出现发育畸形、生长迟缓和代谢通路失调,且胚胎存活率较高。
Perfluorobutanesulfonic acid (经水暴露;持续处理;受精后至受精后 6 天;3000 mg/L) 可诱导斑马鱼幼体活动减退并改变其运动行为。
Perfluorobutanesulfonic acid (经水体暴露;持续暴露;从受精至 120 hpf、从受精至受精后 4 天) 会诱导斑马鱼幼体出现浓度依赖性的过度活跃、活跃度降低以及类癫痫样运动效应。
Perfluorobutanesulfonic acid (经水暴露;持续处理;28 天) 会破坏成年斑马鱼的肠道完整性,改变肠道菌群组成,并引发性别特异性代谢紊乱。
Perfluorobutanesulfonic acid (经水暴露;持续处理;从受精至 120 hpf;0.2-200 μM) 可改变发育中斑马鱼的 PPAR 及胰岛素信号通路。
Perfluorobutanesulfonic acid (经水暴露;持续处理;从受精至受精后 4 天,10 mg/L) 可提高斑马鱼幼鱼的皮质醇水平,表明其应激轴受到破坏。
Perfluorobutanesulfonic acid (经水暴露;持续处理;受精至受精后 5 天,浓度 3000 mg/L) 可诱导斑马鱼胚胎产生发育畸形并降低心率,且死亡率较低,其中畸形效应的 EC50 为 1529 mg/L。

Animal Model: transgenic Tg(insulin:GFP); Tg(ptf1a:GFP) (homozygous populations, embryonic stage)
Dosage: 16 µM; 32 µM
Administration: daily exposure in 0.3x Danieau’s medium; daily; 1 dpf to 7 dpf
Result: Showed high survival rates at 4 dpf without significant differences from controls.
Increased growth retardation, tail deformities, craniofacial defects, and swim bladder and yolk utilization disorders at 4 dpf.
Reduced exocrine pancreas length and elevated abnormal islet morphology at 4 dpf.
Altered multiple gene expressions and upregulated exocrine pancreatic genes by 11-53.7% at 4 dpf.
Activated lipid and xenobiotic metabolism pathways while suppressing p53, glycolysis/gluconeogenesis, and pentose phosphate pathways at 4 dpf.
Animal Model: Danio rerio (embryonic stage)
Dosage: 8.25 µM; 82.5 µM; 825 µM; 8250 µM
Administration: daily exposure in 0.3x Danieau’s medium; daily; 3 hours post fertilization to 5 dpf
Result: Reduced survival, hatching, and swim bladder inflation rates in a concentration‑dependent manner, with an LC50 of 1310 μM for PFBS.
Animal Model: DH1033 (sqt-1(sc103) II; bIs1 X)
Dosage: 1000 μM; 2000 μM
Administration: in S-complete liquid media with heat-killed E. coli; 1 day exposure
Result: Reduced VIT-2::GFP intensity by 25% at 1000 μM compared to control.
Reduced VIT-2::GFP intensity by 23% at 2000 μM compared to control.
Reached internal parent worm concentration of 2.8 ng/mg DNA at 1000 μM and 4.6 ng/mg DNA at 2000 μM.
Animal Model: Danio rerio (early life stage embryos/larvae; exposed from fertilization to 120 hpf)
Dosage: 16 μM; 32 μM
Administration: waterborne; continuous; fertilization to 120 hpf
Result: Achieved 96% survival at 16 μM and 95% at 32 μM.
Caused shorter body length, stunted growth, and increased incidence of blunt and curly tails at both doses.
Induced craniofacial malformations and decreased swim bladder inflation at 16 μM.
Caused impaired yolk utilization and decreased pancreas length at 32 μM.
Downregulated energy metabolism pathways (gluconeogenesis/glycolysis) and p53 signaling at both doses.
Upregulated lipid and xenobiotics metabolism pathways at both doses.
Animal Model: Oryzias melastigma (embryos and adult fish; embryos exposed from fertilization to 15 dpf; adult fish exposed for multi-generational assessment)
Dosage: 1 mg/L; 3.3 mg/L; 10 mg/L (embryos); 9.5 μg/L (adult fish)
Administration: waterborne; continuous; fertilization to 15 dpf (embryos); waterborne; continuous; 6 months (adult fish)
Result: Showed no impact on survival, heart rate, or malformation rate in embryos, but increased hatching rate in a concentration-dependent manner.
Decreased 17β-estradiol (E2) levels at all embryo doses.
Decreased testosterone (T) levels only at 1 mg/L in embryos, and decreased E2/T ratio in a concentration-dependent manner.
Upregulated transcript levels for gnrh isoforms and their receptors, while downregulated steroidogenesis, reproduction, estrogen receptor, choriogenin, and vtg-1 genes at 10 mg/L in embryos.
Reduced plasma 3,5,3′-triiodothyronine (T3) and brain thyroxine (T4) levels in F0 females; increased plasma T4 levels and downregulated hypothalamus-pituitary-thyroid (HPT) signaling in both F0 males and females.
Increased T3 and thyroxine-binding globulin (TBG) levels and downregulated HPT signaling in F1 larvae; resolved most thyroid disturbances but had significantly higher T4 levels in F2 larvae from F0 fish exposed to 9.5 μg/L.
Blocked oocyte development, reduced ovary size, altered follicle-stimulating hormone (FSH) and T levels, and caused predominantly male sex ratio in F0 fish.
Detected 10 ng/g dw PFBS in F0 whole fish, up to 2.9 ng/g dw PFBS in F1 unexposed larvae, and no detectable PFBS in F2 larvae.
Animal Model: Danio rerio (early life stage larvae; exposed from fertilization to 6 days post-fertilization)
Dosage: 3000 mg/L
Administration: waterborne; continuous; fertilization to 6 days post-fertilization
Result: Decreased overall larval activity (hypoactivity).
Showed positive correlation with active swimming speed.
Showed negative correlation with swimming distance, swimming time, and average swimming speed.
Animal Model: Danio rerio (early life stage embryos/larvae; exposed from fertilization to 120 hpf or 4 days post-fertilization)
Dosage: 7 μM; 43 μM; 57 μM; 700 μM; 3500 μM; 7000 μM; 10 mg/L
Administration: waterborne; continuous; fertilization to 120 hpf; waterborne; continuous; fertilization to 4 days post-fertilization
Result: Caused hypoactivity at 43 μM and hyperactivity at 57 μM.
Increased total movement at 3500 and 7000 μM during light phases.
Increased total movement at 7-700 μM and decreased total movement at 3500 and 7000 μM during dark phases.
Caused lethargic phototaxis behavior and reduced locomotor activity at 10 mg/L.
Animal Model: Danio rerio (adult fish; exposed for 28 days)
Dosage: 10 μg/L; 100 μg/L
Administration: waterborne; continuous; 28 days
Result: Decreased tight junction protein 2 (TJP2) in both male and female intestines at 100 μg/L; increased interleukin 1β levels (intestinal inflammation) in females at 100 μg/L.
Increased relative abundances of Acidobacteria and Chloroflexi phyla in females at 10 μg/L; decreased Bifidobacterium abundance in females at 100 μg/L.
Increased abundances of short chain fatty acid-producing bacteria (Bifidobacterium, Blautia, Faecalibacterium) in males at 10 μg/L.
Increased total bile acids in females but decreased total bile acids in males; decreased L-carnitine levels and downregulated apolipoprotein hepatic synthesis in females.
Disrupted bile acid secretion and fatty acid oxidation, increased blood glucose (2.5-fold), and caused hepatic vacuolization in males at 10 μg/L; decreased blood glucagon (2.9-fold) and increased glycogen (3.2-fold) in females at 10 μg/L.
Animal Model: Oryzias melastigma (adult fish; exposed for 7 or 21 days under normoxia)
Dosage: 10 μg/L
Administration: waterborne; continuous; 7 or 21 days
Result: Increased bile acid levels in males after 7 days.
Increased glycerol levels and free fatty acid content after 21 days.
Animal Model: Danio rerio (early life stage embryos/larvae; exposed from fertilization to 120 hpf)
Dosage: 0.2 μM; 2 μM; 20 μM; 200 μM
Administration: waterborne; continuous; fertilization to 120 hpf
Result: Enriched pathways related to PPAR and insulin signaling via KEGG analysis.
Animal Model: Danio rerio (early life stage embryos/larvae; exposed from fertilization to 5 days post-fertilization)
Dosage: 10 mg/L
Administration: waterborne; continuous; fertilization to 4 days post-fertilization
Result: Significantly increased cortisol levels in larvae.
Animal Model: Danio rerio (early life stage embryos; exposed from fertilization to 5 days post-fertilization)
Dosage: 3000 mg/L
Administration: waterborne; continuous; fertilization to 5 days post-fertilization
Result: Caused low mortality.
Significantly decreased heart rate after 72 hpf.
Induced malformations including uninflated swim bladders and tail deformities.
Achieved a median effective concentration (EC50) of 1529 mg/L for malformations, and a lethal concentration 50 (LC50) of > 3000 mg/L.
性状 液体(密度:1.849±0.06 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 300.10
分子式 C4Hf9O3S
CAS No. 375-73-5
别名 PFBS

储存&溶解度

储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (166.61 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.3322 mL16.6611 mL33.3222 mL83.3056 mL
5 mM0.6664 mL3.3322 mL6.6644 mL16.6611 mL
10 mM0.3332 mL1.6661 mL3.3322 mL8.3306 mL
15 mM0.2221 mL1.1107 mL2.2215 mL5.5537 mL
20 mM0.1666 mL0.8331 mL1.6661 mL4.1653 mL
25 mM0.1333 mL0.6664 mL1.3329 mL3.3322 mL
30 mM0.1111 mL0.5554 mL1.1107 mL2.7769 mL
40 mM0.0833 mL0.4165 mL0.8331 mL2.0826 mL
50 mM0.0666 mL0.3332 mL0.6664 mL1.6661 mL
60 mM0.0555 mL0.2777 mL0.5554 mL1.3884 mL
80 mM0.0417 mL0.2083 mL0.4165 mL1.0413 mL
100 mM0.0333 mL0.1666 mL0.3332 mL0.8331 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础